EUCTR2007-001360-76-ITActive, not recruitingNot Applicable
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU377 to placebo after 8 week treatment in patients with essential hypertension - ND
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- OVARTIS FARMA
- Enrollment
- 1,320
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Male or female patients from 18 up to including 75 years Patients with mild-to-moderate uncomplicated essential hypertension, treatment naïve or currently taking antihypertensive therapy (monotherapy or combination therapy of 2 drugs). Treatment naïve patients must have an office mean sitting diastolic blood pressure (MSDBP) ≥ 95 mmHg and < 110 mmHg at the randomization visit (visit 3) and the 2 preceding visits (Visits 1 and 2). Pretreated patients must have an office MSDBP ³ 90 mmHg and < 110 mmHg after washout (Visit 2), and a MSDBP ³ 95 mmHg and < 110 mmHg at baseline (Visit 3) Written informed consent to participate in the study prior to any study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Severe hypertension (MSSBP ≥180 mmHg and/or MSDBP ≥110 mmHg) Known or suspected contraindications, including history of allergy to ARBs, NEPi?s or to drugs with a similar chemical structure. History of angioedema, drug-related or otherwise as reported by the patient Type 1 or Type 2 diabetes mellitus History of angina perctoris, myocardial infarction, coronary bypass surgery, ischemic heart disease, surgical or percutaneaous arterial intervention of any kind (coronary, carotid or peripheral intervention), stroke, TIA (transient ischemic attack), carotid artery stenosis, aortic aneurysm or peripheral arterial disease Women of child-bearing potential (WOCBP) unless they are post-menopausal or use predefined acceptable methods of contraception
Investigators
Similar Trials
Completed
Phase 2
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU377 to placebo after 8 week treatment in patients with essential hypertensiohypertension = high blood pressureincreased arterial pressure10057166NL-OMON31167ovartis50
Active, not recruiting
Phase 1
A Study to Evaluate Mepolizumab Withdrawal After Long-Term Usesevere eosinophilic asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002361-32-NLGlaxoSmithKline Research & Development Ltd306
Active, not recruiting
Phase 1
Study of efficacy and safety of ligelizumab in adolescents and adults with chronic inducible urticaria who remain symptomatic despite treatment with H1- antihistaminesChronic Inducible UrticariaMedDRA version: 20.0Level: PTClassification code 10009869Term: Cold urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10008675Term: Cholinergic urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 23.0Level: LLTClassification code 10012521Term: DermographismSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-003018-11-GRovartis Pharma AG428
Active, not recruiting
Phase 1
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU377 to placebo after 8 week treatment in patients with essential hypertensioEssential HypertensionEUCTR2007-001360-76-SKOVARTIS PHARMA Services AG1,560
Active, not recruiting
Not Applicable
A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in patients with essential hypertensioMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2008-003139-19-NLovartis Pharma Services AG480